Lilly needs a plan to spur weight-loss drug sales, investors say
Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales of popular weight-loss drug Zepbound after it last month forecast lower-than-expected fourth-quarter revenues for the drug.
As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, ...
Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.
Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...
Key Takeaways Pharmaceutical company Eli Lilly is expected to report fourth-quarter earnings before the bell ...
Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback